BCL2 and B-cell chronic lymphocytic leukemia: One of the hallmarks of CLL is dysregulation of apoptosis by overexpression of the anti-apoptotic protein Bcl-2, which renders CLL highly sensitive to the Bcl-2 inhibitor venetoclax (ABT-199).